NEXGEL Q2 Revenue Misses as BioNX Integration Slows, Loss Widens to $2.87M
NXGL sits 52% above its 52-week low of $0.33 on elevated volume (5.2× avg).
Summary
NEXGEL reported Q2 revenue of $3.69 million and a net loss of $2.87 million, with the BioNX Surgical integration progressing slower than expected and a $795,000 backlog due to supply chain constraints. The company also disclosed a strategic recall of all SilverSeal inventory from Amazon costing $144,495, though it plans to launch the product into the hospital channel in August. Shareholders rejected the proposed authorized share increase and reverse split, which management attributes to broker non-votes linked to the redomicile proposal; a standalone resolicitation is planned for late September. The company released $710,000 in restricted cash from ATW Partners and will host an investor update call on September 15, 2026. This follows the going concern warning and potential defaults on $13.9M in convertible notes disclosed in the 10-Q filed August 14.
At the time of this announcement, NXGL was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.33 to $2.89. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.